Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States.
The last earnings update was 12 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Aclaris Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Aclaris Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Aclaris Therapeutics's earnings are expected to grow significantly at over 20% yearly.
Aclaris Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Aclaris Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Aclaris Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Aclaris Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Aclaris Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Aclaris Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 4.6x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Neal S. Walker, D.O., Co-founded Aclaris Therapeutics, Inc. in 2012 and also has been its Chief Executive Officer and President since July 2012. Dr. Walker is also Co-Founding Member and Partner of NeXeption, LLC. Dr. Walker co-founded NeXeption, LLC in August 2012. He is the Co-Founder and Vice Chairman of Ralexar Therapeutics Inc. He Co-founded Octagon Research Solutions, Inc. in 1999. He Co-founded Trigenesis Therapeutics, Inc., where he served as the Chief Medical Officer (acquired by Dr. Reddy's Laboratories Ltd) and Cutix Inc., a commercial dermatology company that markets PreSun , a sunscreen brand acquired from Bristol-Myers Squibb Co. He Co-founded Vicept Therapeutics, Inc. and served as its Chief Executive Officer, President and Director from 2009 to 2012. He has over 16 years of pharmaceutical industry experience in R&D, regulatory affairs and business development. He has many years of business development experience working with large biopharmaceutical companies, start-ups and universities in the identification, acquisition/licensing and financing of novel development stage assets and in-market brands. He is a Board-certified Dermatologist and served as Consultant to number of pharmaceutical companies between July 2011 and July 2012. He served as Medical Consultant of Johnson & Johnson, AstraMerck and AstraZeneca. Additionally, he has served on the Advisory Committee Safety Team for Prescription to OTC switch of Prilosec®. He has also worked with Vanderbilt University's life science fund assisting the venture firm in the identification and due diligence of medically-related technologies and business concepts. He serves as an Executive Chairman of Follica, Inc. He began his pharmaceutical industry career at Johnson and Johnson, Inc. He has been an Executive Director at Aclaris Therapeutics, Inc. since July 2012. He serves as a Director at Sebacia, Inc. and Zoomi, Inc. He has been a Director of Aldeyra Therapeutics, Inc. since June 2013. Dr. Walker is a director of Alderya Therapeutics, Inc. He has been a Director of Pennsylvania Bio since May 2015. Dr. Walker co-founded and led a number of life science companies. He serves as a Director of Dermatology Summit. He serves on Advisory Boards of Specialty Diets, Inc. He served on the Board of Directors for Octagon and the Advisory Board of Flexible Medical Systems. He served as a Director of Octagon Research Solutions, Inc. He served as the Chief Resident of the Dermatology Residency Program at Philadelphia College of Osteopathic Medicine for 2 years. He completed Internship at St. Barnabas Hospital in New York. Dr. Walker received his MBA from The Wharton School, University of Pennsylvania, his Doctor of Osteopathic Medicine degree from Philadelphia College of Osteopathic Medicine and a B.A. in Biology from Lehigh University.
Neal's compensation has increased whilst company is loss making.
Neal's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Aclaris Therapeutics management team is over 5 years, this suggests they are a seasoned and experienced team.
Co-Founder & Chief Scientific Officer
Chief Medical Officer
Co-Founder and Chief Regulatory & Development Officer
Co-Founder & CFO
Senior VP of Corporate Strategy/Investor Relations
Vice President of Marketing
Vice President of Sales
Interim Head of Commercial
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Aclaris Therapeutics board of directors is about average.
Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company’s products under development include ATI-450 MK-2 pathway oral inhibitor for the treatment of rheumatoid arthritis, psoriasis, hidradenitis suppurativa, cryopyrin-associated periodic syndrome, and pyoderma gangrenosum; ATI-1777 JAK1/JAK3 soft topical inhibitor for atopic dermatitis, vitiligo, and alopecia areata; ITK/JAK3 soft topical and oral inhibitors to treat psoriasis and inflammatory diseases; MK-2 pathway oral inhibitor for oncology; and ITK-JAK3 oral gut-restricted inhibitor for ulcerative colitis/Crohn’s disease. Further, it provides contract research laboratory services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.